# OrigAMI-2 (NCT06662786)

> A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06662786
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Colorectal Neoplasms
- Interventions: Amivantamab; Cetuximab; 5-fluorouracil; Leucovorin calcium/Levoleucovorin; Oxaliplatin; Irinotecan Hydrochloride
- Enrollment: 1000
- Primary outcome: Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 10
- YouTube: 7
- Podcasts: 3
- Bluesky threads: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=origami-2-nct06662786

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06662786", "email": "<work email>"}; the inbox owner confirms by the emailed link.